Publications by authors named "Nana Gu"
Article Synopsis
- The immune system helps prevent tumor formation, with PD-L1 and CD47 acting as signals that inhibit immune responses.
- Researchers developed a dual-targeting fusion protein called IAB that targets both PD-L1 and CD47, showing effectiveness in stimulating immune responses and killing tumor cells in lab tests.
- IAB demonstrated strong anti-tumor activity in mice without significant side effects, suggesting that it utilizes both innate (macrophages) and adaptive (T cells) immune responses for better therapeutic outcomes.
Therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancer.
Biochem Biophys Res Commun
November 2016
Immunocytokines (antibody-cytokine fusions) have been proved to be a promising class of therapeutic agents for tumors. Anti-PD-L1 antibodies or IL-2 have been used to treat a variety of cancers. Here, in order to remove T cell inhibition and increasing the IL-2 concentration in the tumor microenvironment, we engineered a novel anti-PD-L1 antibody based immunocytokine by fusing hIL-2 to the C-Term of atezolizumab, denoted as BIPI.
View Article and Find Full Text PDF